![]() ![]() ![]() In addition to leading and supervising the Clinical Research Department, she has responsibility for Clinical Operations, Patient Advocacy, Medical Affairs and Pharmacovigilance. ![]() Allison is responsible for the strategy, direction and execution of the company’s clinical development plans. Mike grew up in northern New Mexico.Īllison is Chief Medical Officer at Comanche Biopharma. Previously, Mike worked for Massachusetts General Hospital (MGH) and the Center for Integration of Medicine and Innovative Technology (CIMIT). Mike has played a leadership role in the development, approval and launch of new therapeutics in the areas of acute cardiovascular, surgery, infectious disease, and anesthetics. Mike held various other positions of leadership in his more than 11 years at MDCO, including Chief Learning Officer and Head of Marketing for the post-operative business unit. Previous to Comanche, Mike was Vice President of Commercial Planning and Healthcare Provider Strategy at The Medicines Company (MDCO) where he was responsible for the global pre-commercialization, go to market planning, lifecycle, and competitive intelligence strategy for Leqvio (Inclisiran) through to its acquisition by Novartis in 2020. Mike is Co-Founder and President of Comanche Biopharma where he is responsible for leading operations and building the company. He currently is a Board member at Atalanta Therapeutics, a biopharmaceutical company focused on the application of RNA interference to diseases of neurodegeneration. He has been Board Certified in Internal Medicine, Pulmonary and Critical Care Medicine and Sleep Disorders Medicine. His academic career included faculty positions at Harvard Medical School, the University of Colorado Medical School, and the University of South Alabama. (Alpha Omega Alpha) from the University of Alabama. in chemistry (Phi Beta Kappa) and an M.D. From September 1991 to July 1999, Scott served as a founder and managing director of MPM Capital, LLC, a venture capital firm. Previously, Scott was a founding General Partner at JSB Partners, L.P., an investment bank with a focus on mergers and acquisitions, private financings and corporate alliances within the healthcare sector. In that role, he was responsible for evaluating the company’s long-range global strategy and for the licensing or acquisition of innovative products, including inclisiran, for which the company was purchased by Novartis. Prior to Comanche, Scott was a co-founder of The Medicines Company where he served as director (1996-2009) until he joined the management team as Chief Medical Advisor (2009-2021). Scott is our CEO and co-founder of Comanche Biopharma. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |